SCHEMBL18112896

SCHEMBL18112896

COc1cc(S(=O)(=O)N(C)C2CCCCC2)ccc1-c1cnc(N)c(-c2ccc3c(c2)CCNC3=O)c1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 1/20 0.47
▸ MAPKAPK2 P49137 4/20 0.40
▸ KCNH2 Q12809 2/20 0.40
▸ FYN P06241 3/20 0.39
▸ ALDH1A1 P00352 1/20 0.38
▸ GSK3B P49841 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ MCOLN3 Q8TDD5 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ MAPT P10636 1/20 0.36
▸ PARP10 Q53GL7 3/20 0.36
▸ PARP11 Q9NR21 3/20 0.36
▸ ALOX5AP P20292 2/20 0.36
▸ FEN1 P39748 2/20 0.36
▸ TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18113043 0.96 MAPK1 (0.49) MAPK1MAPKAPK2KCNH2FYNGSK3B
SCHEMBL18113028 0.92 MAPK1 (0.56) MAPK1MAPKAPK2KCNH2FYNGSK3B
SCHEMBL18113014 0.88 MAPK1 (0.48) MAPK1MAPKAPK2KCNH2GSK3BPARP10
SCHEMBL18112894 0.88 MAPK1 (0.47) MAPK1MAPKAPK2KCNH2FYNGSK3B
SCHEMBL18112920 0.86 MAPK1 (0.51) MAPK1MAPKAPK2KCNH2GSK3BPARP10
SCHEMBL12077934 0.86 MAPK1 (0.54) MAPK1MAPKAPK2KCNH2FYNGSK3B
SCHEMBL18113049 0.85 MAPK1 (0.50) MAPK1MAPKAPK2GSK3BPARP10PARP11
SCHEMBL22209338 0.85 MAPK1 (0.50) MAPK1MAPKAPK2FYNGSK3BPARP10
SCHEMBL12077231 0.84 MAPK1 (0.51) MAPK1MAPKAPK2KCNH2GSK3BPARP10
SCHEMBL12496245 0.83 MAPK1 (0.48) MAPK1MAPKAPK2KCNH2FYNGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016161145-A1 STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-10-06 — — WO claimed
US-10710978-B2 STK4 inhibitors for treatment of hematologic malignancies DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-07-14 — — US disclosed
US-20180111916-A1 STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES FONDAZIONE CENTRO SAN RAFFAELE (IT) 2018-04-26 — — US disclosed
US-20180111916-A1 STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES FONDAZIONE CENTRO SAN RAFFAELE (IT) 2018-04-26 — — US disclosed
WO-2016161145-A1 STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-10-06 — — WO disclosed
WO-2016161145-A1 STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-10-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180111916-A1 STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES STK4, STK3, STK11 MAPK1 341/4885MAPKAPK2 90/4885KCNH2 2512/4885
US-10710978-B2 STK4 inhibitors for treatment of hematologic malignancies STK4, STK3, STK11 MAPK1 341/4885MAPKAPK2 90/4885KCNH2 2512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback